NOVELTY - Preparing (+)-methyl-2-amino-2-(2-chlorophenyl)acetate involves (a1) reacting methyl-2-amino-2-(2-chlorophenyl)acetate with chiral acid in presence of methanol and methyl-iso-butyl-ketone to form chiral acid salt of (+)-methyl-2-amino-2-(2-chlorophenyl)acetate; (b1) treating the chiral acid salt of (+)-methyl-2-amino-2-(2-chlorophenyl)acetate obtained in step (a1) with a base to form (+)-methyl-2-amino-2-(2-chlorophenyl)acetate.    USE - For preparing (+)-methyl-2-amino-2-(2-chlorophenyl)acetate and (+)- alpha -(2-thien-2-yl)-ethyl amino)- alpha -(2-chlorophenyl)methyl acetate or its salts which is useful in preparing clopidogrel or its salts; and for preparing crystalline Form 1 of Clopidogrel bisulphate (claimed). The clopidogrel is useful as an antithrombotic drug.    ADVANTAGE - To reduce the manufacturing cost of the clopidogrel bisulfate at the commercial scale, it is essential to provide a simple and improved process for the preparation of (+)-methyl-2-amino-2-(2-chlorophenyl)acetate and (+)- alpha -(2-thien-2-yl)-ethyl amino)- alpha -(2-chlorophenyl)methyl acetate or its salts, which is economical, ecofriendly and reproducible with high yield and purity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:    (1) preparing (+)- alpha -(2-thien-2-yl)-ethyl amino)- alpha -(2-chlorophenyl)methyl acetate or its salts involving carrying out the steps (a1) and (b1), (c1) reacting (+)-methyl-2-amino-2-(2-chlorophenyl)acetate with 2-(thiophen-2-yl)ethyl para-toluenesulfonate or 2-(thiophen-2-yl)ethyl methylsulfonate to form (+)- alpha -(2-thien-2-yl)-ethyl amino)- alpha -(2-chlorophenyl)methyl acetate, (d1) optionally converting the obtained (+)- alpha -(2-thien-2-yl)-ethyl amino)- alpha -(2-chlorophenyl)methyl acetate in step (c1) into its salts of (+)- alpha -(2-thien-2-yl)-ethyl amino)- alpha -(2-chlorophenyl)methyl acetate;    (2) preparing clopidogrel or its salts involving carrying out the steps (a1)-(c1), (d2) cyclizing (+)- alpha -(2-thien-2-yl)-ethyl amino)- alpha -(2-chlorophenyl)methyl acetate or its salts in presence of formaldehyde to produce Clopidogrel; (e2) optionally converting the obtained clopidogrel in step (d2) into a clopidogrel bisulfate;    (3) preparing crystalline Form 1 of Clopidogrel bisulphate involving (a3) providing a solution of clopidogrel freebase in an ketone solvent, (b3) optionally, treating the solution obtained in step (a3) with charcoal, (c3) adding butylated hydroxy toluene the solution obtained in step (b3), (d3) adding sulfuric acid to the solution obtained in step (c3), (e3) optionally, seeding the solution obtained in step (d3) with crystalline Form 1 of clopidogrel bisulphate; and (f3) isolating the crystalline Form 1 of Clopidogrel bisulphate.